Compare Crestor vs Repatha head-to-head with other drugs for uses, ratings, cost, side effects and interactions. Tableau 3. Compare Repatha vs Zetia head-to-head with other drugs for uses, ratings, cost, side effects and interactions. Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has been looking for a leg up in a wide-ranging clinical program involving dozens of trials. Amgen's Repatha and Sanofi and Regeneron's Praluent have been locked in a heated battle for supremacy in the pricey PCSK9 cholesterol-cutting market. Repatha (evolocumab) is a prescription medication used to lower LDL cholesterol and reduce the risk of heart attack in adults. Repatha and Praluent can be used on their own or in conjunction with lipid-lowering therapies (e.g., statins, ezetimibe). Repatha a diminué de manière significative les valeurs de CT, d'ApoB, de non-HDL-C, de CT/HDL-C, d'ApoB/ApoA1 et de Lp(a), entre la valeur initiale et la moyenne des semaines 10 et 12 par rapport à un placebo et à l'ézétimibe (p < 0,001) (voir le tableau 3). Crestor rated 6.0/10 vs Repatha rated 4.5/10 in overall patient satisfaction. Repatha and Praluent are both from the same drug class which is PCSK9 ; Repatha and Praluent should both be used in conjunction with a diet aimed at reducing cholesterol and triglycerides. Repatha rated 4.5/10 vs Zetia rated 5.0/10 in overall patient satisfaction. Nexletol is also seen as a possible alternative for patients who don't respond well to other cholesterol-lowering drugs. Nexletol and Nexlizet are sold at a wholesale acquisition cost of $10 per day, a price the drugmaker said was far below that of PCSK9 meds Repatha and Praluent.